Find-A-Study

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Lay Description

The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.

Eligibility

Eligible Ages: Between 18 Years and 80 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Type 2 Diabetes Mellitus
Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) <50%
Age 18-80 years
BMI 23-38 kg/m2
Glycated hemoglobin (HbA1c) 5.5-10%
Blood Pressure (BP) ≤ 145/85 mmHg
Estimated glomerular filtration rate (eGFR) ≥30 ml/min•1.73 m2
Stable dose of guideline-directed medications for heart failure
Stable body weight (±4 pounds) over the last 3 months

Exclusion Criteria

Subjects treated with an SGLT2 inhibitor, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or pioglitazone
Resting heart rate >120 bpm
Systolic BP>180mmHg and/or diastolic BP >100mmHg
Resting percentage of blood oxygen saturation (SpO2) < 85%
Physical disability preventing safe performance of the exercise protocol.

Study Design

Arm Groups

Study Contact

Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu

Principal Investigator
Carolina Solis-Herrera